loading

Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스

pulisher
May 02, 2025

An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - Sete News

May 02, 2025
pulisher
May 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Zentalis Expands Cancer Drug Development Team with Strategic New Hire Grant Worth $20,000 - Stock Titan

May 01, 2025
pulisher
May 01, 2025

Was anything positive for Zentalis Pharmaceuticals Inc (ZNTL) stock last session? - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Zentalis Pharmaceuticals Inc [ZNTL] Director makes an insider purchase of 21,000 shares worth 29373.0. - knoxdaily.com

May 01, 2025
pulisher
May 01, 2025

Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock By Investing.com - Investing.com Canada

May 01, 2025
pulisher
Apr 30, 2025

Zentalis pharmaceuticals director Scott Myers acquires $29,372 in stock - Investing.com Australia

Apr 30, 2025
pulisher
Apr 29, 2025

Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

Ratios Revealed: Decoding Zentalis Pharmaceuticals Inc (ZNTL)’s Financial Health - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Zentalis shares insights on cancer research at AACR - Investing.com Australia

Apr 29, 2025
pulisher
Apr 29, 2025

Zentalis (ZNTL) Advances with Phase 2 Trial in Ovarian Cancer | - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Zentalis shares insights on cancer research at AACR By Investing.com - Investing.com Canada

Apr 29, 2025
pulisher
Apr 28, 2025

Zentalis Pharmaceuticals Doses 1st Patient in Part 2 of Ovarian Cancer Clinical Trial - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Zentalis Doses First Patient In Phase 2 DENALI Trial Of Azenosertib In Cyclin E1+ PROC - Nasdaq

Apr 28, 2025
pulisher
Apr 28, 2025

Zentalis Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough: New Cancer Drug Achieves 35% Response Rate in Hard-to-Treat Ovarian Cancer Patients - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Purchased by Geode Capital Management LLC - Defense World

Apr 28, 2025
pulisher
Apr 28, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Apr 28, 2025
pulisher
Apr 27, 2025

Levi & Korsinsky Announces an Investigation on Behalf of Zentalis Pharmaceuticals, Inc. (ZNTL) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Cerity Partners LLC Makes New $40,000 Investment in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 27, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 26, 2025

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) Has Seen A Fall Of -88.62% This Year, Is It Still A Better Option Than Others? – Marketing Sentinel - Marketing Sentinel

Apr 26, 2025
pulisher
Apr 26, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Increased by Russell Investments Group Ltd. - Defense World

Apr 26, 2025
pulisher
Apr 24, 2025

Zentalis Pharmaceuticals Inc (ZNTL) deserves deeper analysis - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Chief Medical Officer Bruns Ingmar acquire 20,000 shares of Zentalis Pharmaceuticals Inc [ZNTL] - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Zentalis Pharmaceuticals Announces Poster Presentation at ASCO 2025 on Azenosertib for Colorectal Cancer - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

New Clinical Data: Zentalis's Novel Cancer Drug Shows Promise in Metastatic Colorectal Cancer Treatment - Stock Titan

Apr 23, 2025
pulisher
Apr 23, 2025

JPMorgan Chase & Co. Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 23, 2025
pulisher
Apr 19, 2025

Franklin Resources Inc. Buys Shares of 106,748 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 19, 2025
pulisher
Apr 14, 2025

Raymond James Financial Inc. Takes Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

12,840 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Acquired by Prudential Financial Inc. - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

Sei Investments Co. Purchases Shares of 35,320 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 12, 2025
pulisher
Apr 10, 2025

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL): Can The Stock Still Lose Despite An -61.39% YTD Loss? - Marketing Sentinel

Apr 10, 2025
pulisher
Apr 08, 2025

Zentalis stock plunges to 52-week low at $1.08 amid market challenges - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

Lost Money on Zentalis Pharmaceuticals, Inc.(ZNTL)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 08, 2025

ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 07, 2025

Investor’s Delight: Zentalis Pharmaceuticals Inc (ZNTL) Closes Weak at 1.17, Down -8.95 - DWinneX

Apr 07, 2025
pulisher
Apr 05, 2025

Thrivent Financial for Lutherans Grows Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 05, 2025
pulisher
Apr 03, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025
pulisher
Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Forecast for ZNTL Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc. - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World

Mar 30, 2025
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
자본화:     |  볼륨(24시간):